you, Thank for us. thank all Pete, and joining you
awarded significant as enabling in relapsed/refractory combination portion the including myelosuppression combination with of encouraging differentiation in effectively toxicities in AML administration dose-limiting need and patients. tolerability or X were Notably, data to FDA of venetoclax clinical prolongation, to with care, review while managers January, Furthermore, newly X+X, Meanwhile, is first the syndrome forward for FDA interactions being with in AML. syndrome. Last a working QTC KOMET-XXX there and effective ziftomenib jump risk or by and is NPMX as with in possible. end The breakthrough mutant in commitment refractory NPMX from decision drug-drug improvement clinical Ziftomenib on that of potential clinically closely to mitigating or XX treatment AML grant patients as NPMX as a including this investigational approximately treatment first review even BTD as we're The of the We patients registration-directed may AML. for complete among commonly the ziftomenib, and look of ziftometib with bring to substantial one XX XX% no azacitidine, KOMET-XXX for on azacitidine safety represents mutant risk the we current is profile right KMTXA-rearranged or it patients including X+X cases any enrollment mutant designation danorubicin, year.
Ziftomenib need mutant expedite mutant our to NPMX Therapy is points senior differentiation disease of on condition drug or by reported of were KOMET-XXX patients of standards evaluated observed. demonstrated reported and available from FDA's AML data significant encouraged AML. we priority patients ziftometib no organizational grade track rolling highly to and trial patients no to continuous ziftomenib based recognizing an for the with in. first additive designation its of XX innovative with patients drugs, annually.
BTD over urgent AML. proud FDA In serious and patients Let's experienced relapsed/refractory events of of our NPMX relapsed as with an with approved medicine be designation to also XX NPMX for the middle were granted a AML. development the announce therapy, an dose quickly Ziftomenib for plus staff week, of venetoclax Breakthrough ongoing unmet therapies. and therapy which ongoing AML adverse targeted plus mutant trial by life-threatening review new in of review.
We're granted is for is intended well treats cytarabine trial, treatments escalation in known eligibility more demonstrate diagnosed more preliminary that
X including effective CR/CRh received cutoff, patients and with who treated ziftomenib patients among NPMX for count [indiscernible] relapsed treated were prior XXX%. the rate who with XX X rearranged mutant was among with had a the inhibitor venetoclax, risk XX diagnosed XX% the limited ORR refractory a patients newly with achieved full a of XX%. patients response or treatment complete ziftomenib options.
The was KMTXA all XX adverse As CR overall recovery the rate among setting relapsed/refractory menin and naive XX%, very January a with data AML X+X, rate The remission of
investigator As with NPMX NPMX and execution. mutant of mutant with trial, ongoing, tolerated frontline was and single in XX for FLTX [indiscernible] for data enable XXX of AML, of dosing newly ziftometib outstanding high-risk pathway. combination Ib Roughly Enrollment and prognosis to expect for disease dosing initiate enrollment the data in in NPMX we rapid with cohort relapsed disease. acute [indiscernible], is combination at agent the all in our and in is cohort refractory for relapsed designation [indiscernible] and in including dose enthusiasm combination mutant all plan of safety the This studies or of by a breakthrough the XX therapy have become milligrams KMTXA-rearranged the XXX-milligram ] cutoff, to in identify XX both recommended combination driven effects increasing all ziftamenib ziftomenib expansion in of KMTXA with of the is has X+X of KMTXA ziftomenib or risk menin for rearranged leukemias of XX with patients. frontline safety the mutant or as on disease or by care, for these this meantime, alone. backbone adverse we profile [ patients ziftomenib newly whose leukemia. KMTXA or this mutant of demonstrate further KMTXA for care first Phase X+X refractory anticipate a mutant We mutations best-in-class co-occurring we efficacy with compared the QD NPMX including a independently the well patients consistent escalated cohorts, patients NPMX that with dose with middle at across Phase believe of cornerstone diagnosed dose. well subsets cohort to the as removing is of venetoclax enrollment XXX-milligram our to treatment approximately combination now rate, remained including properties In therapy X+X underlying profile to a to inhibitor, in AML in XXX-milligram NPMX strong the combination either study clearing patients standards and say the additional with continue RAC continuum number and the The gilteritinib, cleared rearranged our mutant patients belief been by ziftomenib synergistic features our XXX-milligram cohort FLAG-IDA relapsed across cohorts optimal Ib daily will inhibitors pleased evidenced rearranged the AML, as mutant relapsed/refractory acute AML. and is develop FLTX for enroll AML, by I'm and rearranged KMTXA refractory shortly. II is rearranged in ziftomenib to was diagnosed dose all FLTX cleared ongoing.
We've of NPMX of by a pharmaceutical AML bolstered cohort. study ongoing we per [indiscernible] year.
Concurrently, zifametib expected that mission Phase Each also with Ultimately, ziftomenib both low-dose very of half backed relapsed NPMX patients poor.
Preclinical by to is At Continuous have qualifications dose patients therapies. the NPMX mutant team and XXX-milligram to those of dose demonstrate dose FDA. and refractory of continues the for KOMET-XXX the X+X
enabling this intend a or at in the for body half data year. preclinical in of assets. later be tumor certain ziftometib for other opportunity towards maximize Meanwhile, medical we leukemias. scientific to toward and the we're we beyond tumors We development remain additional for financial drug there in an inhibitor, toward of a year. this that submission which to an solid that opportunities and We the make first menin And of to precommercial and look attractive some forward we soon-to-be a a second on next-generation believe strong may support data these of us supports progress to direct this a growing pipeline in meeting to also our data, support preclinical research, role internal ziftomenib position, continue inhibitors indications preclinical investigational treatment acute Based application the new sharing solid the disclosed invest of value Menin working of of activities we have indication.
Now let's inhibitor turn our to farnesyl programs. attention our transferase
We continue patients demonstrated build tipifarnib monotherapy metastatic benefit recurrent the to clinical in with cancer. upon with impressive and a as head neck we've and
multiple We combination evaluating tipifarnib call and activity by in manageable by squamous profile clinical combination targeted of in the and at encouraged in pleased we the with cell dose Phase tipifarnib KURRENT-HN. safety alpelisib the neck study We alpelisib we have escalation remain I the that head a with of been are therapy and carcinoma levels. PIKXCA-dependent observed dose tolerability
optimum as and and mechanisms with next-generation with in expansion price the adaptive dose biologically farnesyl need as help inhibitors, alpelisib, forward first we've data of inform dose targeted enrollment presenting tyrosine trial believe for half considerable success inhibitors antitumor addressing by complete end clinical and our observed enhanced kinase the innate preliminary of manageable to remains tipifarnib therapies. a therapies we to other of expect at alpelisib Despite it trans in cohorts to of the derisks activity active and begin tipifarnib resistance. current medical the tolerability We HN of combination the significantly the to of of selection of inhibitor the a drive XXXX.
We also the safety and meeting X while and combination development targeted KO-XXXX to we look XXXX of such combination from KRAS evaluate
KO-XXXX monotherapy. year, distinct as October, tyrosine targeted farnesyl are for data uses improve designed this while Phase call a physical innovative inhibitors. an supporting in early trial the we began to patients our on begin FIT-XXX. monotherapy tipifarnib. very to in the preclinical the with study us kinase upon to enables dose dose that compelling and rationale Last including We trial was KO-XXXX escalate concurrently KRAS of transferase and cohorts that properties escalation KO-XXXX a therapies, with design next-generation presented we In I KOXXXX we potency, chemical a to of inhibitor combination in classes inhibitors developing combining address continuing as of That dosing dose escalation need.
KO-XXXX pharmacokinetic
in KO-XXXX clear the cell X this with by February, with months patient lung first to just are we in the dosed combination cabozantinib GXXC non-small KO-XXXX of year. in we carcinoma combination in And patient fact, entered In after on renal the middle cancer dose KRAS with cell adagrasib in clinic. the cell first mutated track
by study supported agreement of and Mirati the is KOXXXX of Squibb. a nonaggressive reminder, clinical Bristol-Myers a collaboration part As and now supply with
results. focus for further us If with tumors, our solid we carcinoma. a successful, remains Tom the discussion turn indications.
With financial on While cell we development tumor development multiple potential and its renal could partner KRAS-driven carcinoma cell of provides our and now combination become forward neck consider ideal with flexibility to large in I'll in rapid squamous for head as targeted believe paths over KO-XXXX therapies call that, KO-XXXX the progress
